Abstract 323P
Background
The re-biopsy of metastatic focus for advanced breast cancer has become an international consensus. However, which metastatic lesion is optimized and the security of biopsy have not been widely reported. This study summarized the pathological information of patients who underwent biopsy for new lesions.
Methods
A total of 1673 patients were hospitalized in our single department from 2010 to 2018 with advanced breast cancer diagnosed by imaging. All patients signed informed consent of biopsy. Then needle core biopsy was performed. And the distribution of the acquisition sites, pathological information and security of each puncture site were investigated.
Results
In summary, pathologic diagnostic rate of new lesions was evaluated for 70.5% in our department. A total of 2019 histopathological specimens were obtained. The distribution of the acquisition sites were liver 594 cases, lymph nodes 572 cases, chest wall 422 cases, and lung 182 cases, and the biopsy rates were 63.4%, 50.5%, 63.7% and 18.4%, respectively. Among all the samples, 150 cases (7.4%) were benign tumors or normal tissues, and 28 cases (1.4%) were diagnosed second primary malignancies, of which lung cancer and ovarian cancer were most diagnosed. 1848 specimens (91.5%) were pathologically diagnosed as breast cancer metastasis, which contained liver, lung, lymph nodes, chest wall, skin and other soft tissues and so on. Only a few serious biopsy complications occurred. among all cases, only 1 case of locally hepatic hemorrhage was found in the biopsy of liver masses, while 2 cases of mild pneumothorax were found in the biopsy of lung masses. All of the complications were cured after symptomatic treatment, and the anti-cancer treatment in these patients was no delay.
Conclusions
To some extent, there is a misdiagnosis rate in imaging diagnosis of advanced breast cancer. In addition, the presence of secondary primary malignancies, especially in the lung and pelvic masses, makes re-biopsy more valuable. Therefore, the biopsy of metastatic sites and immunohistochemical redetection should be emphasized, and the security of visceral puncture, such as liver or lung, is as well as superficial tissue.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.